The Seattle Genetics world headquarters in Bothell’s Cascade Park is a cluster of beautiful beige of buildings with no indication of edgy science. But building three lobbies has green triangular sculpture showcasing its geek cred and designed with Lego bricks with a simplified beauty of human antibody.
The human antibodies at the Seattle Genetics have been manipulating, studying and packaging of drugs since its inception in 1998 and just like the Lego bricks the company power of antibodies resides within each other and the ability to swiftly connect with other things. The antibody uses therapy to deliver the toxic payload directly into a personas cancer cell hence destroying them from inside.
The company boasts of the market value of more than 10 billion dollars with a roaster of nine hundred employees globally, and it’s ranked in Washington amongst the biggest biotech. Seattle Genetics main ambition is to graduate from a biotech company to one of the biggest pharmacies globally with its substantial investment in marketing and research and its ability to add 200 trained and expert’s employee. The company flagship drug Adcetrics is known to treat Hodgkin lymphoma, cancer that affects the lymph system and quickly spreads all over to other body organs.
According to Clay Siegall, president, chief executive officer, chairman and the co-founder of the Seattle Genetics, the company is emerging globally offering various multi products. He states that his desire is for the company to move from biotech and focus more on drug development hence handling of more complex and newer drugs in the international market. The company recently opened offices in Switzerland with the aim of doing its international marketing making it a sign of global commitment. The company has 11 drugs in the pipeline with Adcetrics already approved by (FDA) Food and Drug Administration and Siegall predicts a sale of more than 1 billion annually.
Dr. Siegall with others in 1998 started the Seattle Genetics, and he holds the highest positions and also seats on Board of Directors. Under the leadership of Clay Siegall, the company has in pipeline various antibody therapies for cancer that includes the brentuximab vedotin approved in 2011 by FDA. Dr. Clay Siegall also guided the company to secure private and public financing of 675 million dollars during its 2001 initial public offering. He has Genetics Ph.D. from the University of George Washington, and from the University of Maryland he holds Zoology B.S., and he serves on various private Biotechnologies as the board of director. He owns at least 15 patents and has authored 70 publications.